China's President Xi Jinping arrived in Pyongyang on Thursday morning for a state visit to North Korea — the first by a Chinese state leader in 14 years. Experts say the move...Asia Politicsread more
Gold prices spiked in the afternoon of Asian trading hours on Thursday after a dovish U.S Federal Reserve opened the door to further rate cuts, and the 10-year Treasury yield...Metalsread more
The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
"No U.S. drone was operating in Iranian airspace today," a U.S. Central Command spokesman said, according to NBC News.World Politicsread more
The Fed left interest rates unchanged at its monetary policy meeting. The U.S. central bank did, however, drop the word "patient " from its statement and said it would "act as...Asia Marketsread more
As the presidents of U.S. and China near a highly anticipated meeting on trade, the gap in both sides' expectations regarding a deal remains wide.World Politicsread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday — breaching a key psychological level.Bondsread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
Meatless alternatives are on the rise, fueled by startups and companies. CNBC's Uptin Saiidi tried out 21 days as a vegetarian and explores whether this is a fad or the future...Food & Beverageread more
Amazon and Blue Origin founder Jeff Bezos gave more insight into his space company's lunar plans on Wednesday.Technologyread more
(Adds details, comment from Roche)
ZURICH, Feb 25 (Reuters) - Roche Holding AG said on Monday it will buy Spark Therapeutics in a $4.3 billion deal, as the Swiss drugmaker builds its haemophilia portfolio and seeks to keep pace in gene therapy.
Roche will acquire U.S.-based Spark for $114.50 per share, a premium of about 122 percent to Spark's closing price on Feb. 22, the Swiss company said in a statement.
Roche already sells Hemlibra, a drug against haemophilia A that helps stop bleeding in patients with the life-threatening genetic disorder that prevents their blood from clotting properly.
With Philadelphia-based Spark, Roche jumps into a crowded haemophilia gene therapy market, as other players Biomarin Pharma, Uniqure NV and Sangamo have prospective treatments in the works.
"Spark Therapeutics' haemophilia A programme could become a new therapeutic option for people living with this disease," Roche Chief Executive Severin Schwan said in the statement.
Spark's shares traded last week around $50, well off their July high of more than $95 per share. The U.S.-company's stock tumbled last year after announcing two out of 12 patients showed an unfavourable immune response when treated with a higher dose of Spark's haemophilia therapy SPK-8011.
Spark's $850,000-per patient gene therapy Luxturna, which is sold in the United States by Spark and elsewhere by Novartis after its approval in 2017, is a one-time treatment for a rare genetic disease that causes blindness in about 1 in 200,000 people.
Among Spark's top drug hopefuls in the clinic is SPK-8011, for haemophilia A, that is expected to start Phase 3 trials in 2019. It is also working on a therapy for haemophilia B, as well as treatments for Pompe disease, blindness-causing choroideremia and Huntington's disease, among others. (Reporting by John Miller; editing by Thomas Seythal and Rashmi Aich)